However, this attempt failed and this approach did not prove successful until the introduction of the incretin hormone glucagon-like peptide-1 (GLP-1) as the basis for glucose-lowering therapeutics in type 2 diabetes. This evidence concerns the gene GIP and type 2 diabetes mellitus.